China Universal Asset Management Co. Ltd. Has $458,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

China Universal Asset Management Co. Ltd. lifted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 64.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,285 shares of the company’s stock after acquiring an additional 5,582 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in SpringWorks Therapeutics were worth $458,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in SpringWorks Therapeutics by 5.1% during the first quarter. Principal Financial Group Inc. now owns 16,944 shares of the company’s stock worth $834,000 after buying an additional 824 shares during the last quarter. FORA Capital LLC raised its holdings in SpringWorks Therapeutics by 21.2% during the first quarter. FORA Capital LLC now owns 27,894 shares of the company’s stock worth $1,373,000 after buying an additional 4,870 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in SpringWorks Therapeutics by 28.7% during the first quarter. Mutual of America Capital Management LLC now owns 82,655 shares of the company’s stock worth $4,068,000 after buying an additional 18,441 shares during the last quarter. SG Americas Securities LLC raised its holdings in SpringWorks Therapeutics by 8.3% during the first quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $230,000 after buying an additional 358 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in SpringWorks Therapeutics by 79.5% during the first quarter. Sei Investments Co. now owns 48,662 shares of the company’s stock worth $2,395,000 after buying an additional 21,558 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on SWTX. Wedbush restated an “outperform” rating and set a $77.00 price objective (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. JPMorgan Chase & Co. upped their target price on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $68.50.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX opened at $30.48 on Thursday. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -5.93 and a beta of 0.78. The company has a fifty day moving average price of $34.58 and a 200-day moving average price of $37.97.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.58. The company had revenue of $59.73 million for the quarter, compared to the consensus estimate of $34.42 million. SpringWorks Therapeutics’s quarterly revenue was up 59732900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.25) EPS. On average, research analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.